| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2016-04-18 | AC Immune (Switzerland) Biogen (USA - MA) | radiopharmaceutical diagnostic programs (alpha-synuclein PET tracer and TDP-43 PET tracer) | Parkinson's disease, amyotrophic lateral sclerosis (ALS) | R&D |
Neurodegenerative diseases - Diagnostic | R&D agreement |
| 2016-04-18 | Heptares Therapeutics (UK), a wholly-owned subsidiary of Sosei Group (Japan) Kymab (UK) | antibody therapeutics targeting G protein-coupled receptors (GPCR) | R&D |
Cancer - Oncology | R&D agreement | |
| 2016-04-18 | Enterome Bioscience (France) Vertex Pharmaceuticals (USA-MA) | novel small molecule FimH antagonists including EB 8018 | inflammatory bowel disease | R&D licensing commercialisation |
Digestive diseases - Gastrointestinal diseases - Inflammatory diseases | Licensing agreement |
| 2016-04-18 | Adaptimmune Therapeutics (UK) | nomination |
Cancer - Oncology | Nomination | ||
| 2016-04-18 | British Biosimilars Association (BBA) (UK) | opening of new premises |
Opening of new premises | |||
| 2016-04-18 | GSK (UK) | respiratory manufacturing facility in Ware | opening of new premises |
Allergic diseases - Inflammatory diseases - Respiratory diseases | Opening of new premises | |
| 2016-04-18 | Catalyst Biosciences (USA - CA) | nomination |
Nomination | |||
| 2016-04-16 | Evotec (Germany) Exscientia (UK) | first-in-class bispecific small molecule immuno-oncology therapies | research - R&D - collaboration | Cancer - Oncology | Research agreement | |
| 2016-04-15 | Genomics (UK) DNAnexus (USA - CA) | population-scale sequencing data analysis | collaboration |
Technology - Services | Collaboration agreement | |
| 2016-04-14 | Apollo Therapeutics | nomination |
Nomination | |||
| 2016-04-14 | Pierre Fabre laboratories (France) VibioSphen (France) | "Nature Open Library" | collaboration R&D |
Infectious diseases | Collaboration agreement | |
| 2016-04-14 | Merck KGaA (Germany) | nomination |
Cancer - Oncology | Nomination | ||
| 2016-04-14 | Kymab (UK) | nomination |
Cancer - Oncology - Infectious diseases | Nomination | ||
| 2016-04-14 | Akari Therapeutics (USA - NY - UK) XL-protein (Germany) | coversin (recombinant protein derived from the saliva of the Ornithodoros moubata tick) | licensing development commercialisation |
Rare diseases - Autoimmune diseases - Inflammatory diseases - Neurological diseases | Licensing agreement | |
| 2016-04-14 | Merrimack Pharmaceuticals (USA - MA) Leica Biosystems (Germany) | companion diagnostic assays including companion diagnostic assay for seribantumab, or MM-121 | development |
Cancer - Oncology - Diagnostic | Development agreement | |
| 2016-04-13 | Sanofi (France) Stevenage Bioscience Catalyst (UK) | collaboration opening of new premises |
Cancer - Oncology - Cardiovascular diseases - Immunological diseases - Infectious diseases - Neurodegenerative diseases - Rare diseases | Collaboration agreement | ||
| 2016-04-12 | GE Healthcare (USA - WI) | construction of new premises |
Technology - Services | Construction of new premises | ||
| 2016-04-11 | Celgene (USA - NJ) Juno Therapeutics (USA - WA) | Chimeric Antigen Receptor Technology (CAR-T) including CD19 and CD22 directed CAR-T product candidates and T Cell Receptor (TCR) technologies | development commercialisation |
Autoimmune diseases | Exercise of an option agreement | |
| 2016-04-11 | Gyros Protein Technologies (Sweden) | nomination |
Technology - Services | Nomination | ||
| 2016-04-11 | Regeneron Pharmaceuticals (USA - NY) Intellia Therapeutics (USA - MA) | CRISPR/Cas gene-editing technology for in vivo therapeutic development | licensing collaboration |
Technology - Services | Licensing agreement |
